The company will present findings of study into cannabinoid treatment for companion animals at AVA Innovation Symposium next month.
Showing 25 of 270
Having secured a substantial growing capacity over two sites and an industry-leading pharmaceuticals bio-manufacturing facility, THC Global is in a prime position to service domestic patients and the export market.
Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™.
The company expects to receive its final Australian cannabis licenses and permits in the near-term.
THC has partnered with a Malaysian bio-tech firm to deliver medicinal cannabis products.
Stage 1 initial annual yield expected to be 37,000 kilograms dried cannabis flower with an estimated revenue of $287 million.
The company is pleased with data it has collected to date for NanaBis.
The purchase follows the recent appointment to CEO of ex Teva Pharmaceutical executive, Ido Kanyon.
Ilera is a vertically integrated medicinal cannabis company with operations based in Pennsylvania and Louisiana.
The company has secured significant cultivation capacity over two grow sites and an industry-leading bio-manufacturing facility.
Building an intellectual property portfolio is part of Zelda's vertically integrated strategy.
This program gives Asterion Australia the opportunity to supply its planned facility in South East Queensland with disease-free plantlets and genetically standardized marijuana strains
The development and distribution deal is in the form of a heads of agreement.
THC is developing its medicinal cannabis strategy in Australia, New Zealand and Canada and is looking to Asian markets.
This is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well underway.
The study identifies a novel role for the CB2 cannabinoid receptor in HER2+ breast cancer, putting the company at the forefront of efforts to develop new cannabis treatments.
Ido Kanyon will replace interim CEO Dr Paul MacLeman on 22 May 2019.
The company’s cash at bank was $4.41 million at the end of the 2018 calendar year.
AC8 has all the necessary licenses to grow and manufacture cannabinoid medicines in Australia.
New research corroborates the company’s direction of studying the use of NRGBiotic™ to improve gut health.
CPAT-01 is CP1’s lead pharmaceutical product and is derived from cannabinoids.
The ICCI provides access to a global network of specialist services.
AusCann is a fully integrated early-mover pharmaceutical cannabinoid company.
The Vancouver-based medicinal cannabis grower’s Queensland facility will be the world's largest greenhouse cannabis operation, covering a 99-acre site
The property is set to be used for production of medicinal cannabis